Clinical Trial Update: Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating tolerability and efficacy of BVS857 in patients with a hypercatabolic state related to severe burns was terminated. Results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burn Injury

Drugs mentioned

• BVS857

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypercatabolic Status Related to Severe Burn | Phase 2 | Status: TERMINATED | Results posted: 2016-03-07